Document is current
Any future updates will be listed below
-
Authors
Orkild, Benjamin https://orcid.org/0009-0005-9450-9047
Arefeen Sultan, K M
Kholmovski, Eugene https://orcid.org/0000-0001-7581-6096
Kwan, Eugene
Bieging, Erik
Morris, Alan
Stoddard, Greg
MacLeod, Rob S.
Elhabian, Shireen
Ranjan, Ravi https://orcid.org/0000-0002-3321-2435
DiBella, Ed https://orcid.org/0000-0001-9196-3731
-
Funding
Funding for this research was provided by:
National Institutes of Health (R01HL162353, 5F31HL162527)
- License Information
-
More Information
Article History
Received: 2 December 2023
Accepted: 11 December 2024
First Online: 21 December 2024
Declarations
:
: This retrospective study was approved by the University of Utah Internal Review Board (IRB).
: This study was retrospective and was thus conducted on already available MRI data in the University of Utah Hospital database, so no patient consent was necessary. All MRI scans were de-identified.
: Ravi Ranjan has research grants and/or consults for Biosense Webster (Johnson and Johnson), Abbott (St Jude), Medtronic, and Boston Scientific. Alan Morris has equity interest in Marrek, Inc., which has licensed technologies from the University of Utah for performing 3D LGE-MRI of left atrium and quantification of fibrosis/scar from such scans. Alan Morris also serves as a consultant for Marrek, Inc. Eugene Kholmovski has equity interest in Marrek, Inc., which has licensed technologies from the University of Utah for performing 3D LGE-MRI of left atrium and quantification of fibrosis/scar from such scans. Eugene Kholmovski also serves as a consultant for Marrek, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
